Pretreatment expression of 13 molecular markers as a predictor of tumor responses after neoadjuvant chemoradiation in rectal cancer

Annals of Surgery

Volumn 259, Issue 3, 2014, Pages 508-515

  Huh, Jung Wook ^a   Lee, Jae Hyuk ^b   Kim, Hyeong Rok ^a,b  

^a Sungkyunkwan University   (South Korea)

^b Chonnam National University   (South Korea)

Author keywords

molecular marker; neoadjuvant chemoradiation; prediction; rectal cancer; response

Indexed keywords

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CHEMORADIOTHERAPY; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; PROGNOSIS; RECTAL NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, NEOPLASM; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84894025730     PISSN: 00034932     EISSN: 15281140     Source Type: Journal    
DOI: 10.1097/SLA.0b013e31829b3916     Document Type: Article

References (39)

1. Habr-Gama A, Perez RO, Nadalin W, et al. Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results. Ann Surg. 2004;240:711-717.
2. Huh JW, Jung EJ, Park YA, et al. Preoperative chemoradiation followed by transanal excision for rectal cancer. J Surg Res. 2008;148:244-250. (Pubitemid 351915759)
3. Kim CJ, Yeatman TJ, Coppola D, et al. Local excision of T2 and T3 rectal cancers after downstaging chemoradiation. Ann Surg. 2001;234:352-358.
4. Maretto I, Pomerri F, Pucciarelli S, et al. The potential of restaging in the prediction of pathologic response after preoperative chemoradiotherapy for rectal cancer. Ann Surg Oncol. 2007;14:455-461. (Pubitemid 46175289)
5. Huh JW, Park YA, Jung EJ, et al. Accuracy of endorectal ultrasonography and computed tomography for restaging rectal cancer after preoperative chemoradiation. J Am Coll Surg. 2008;207:7-12.
6. Huh JW, Min JJ, Lee JH, et al. The predictive role of sequential FDG-PET/CT in response of locally advanced rectal cancer to neoadjuvant chemoradiation. Am J Clin Oncol. 2012;35:340-344.
7. Negri FV, Campanini N, Camisa R, et al. Biological predictive factors in rectal cancer treated with preoperative radiotherapy or radiochemotherapy. Br J Cancer. 2008;98:143-147.
8. Bertolini F, Bengala C, Losi L, et al. Prognostic and predictive value of baseline and posttreatment molecular marker expression in locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy. Int J Radiat Oncol Biol Phys. 2007;68:1455-1461. (Pubitemid 47176800)
9. Smith FM, Reynolds JV, Kay EW, et al. COX-2 overexpression in pretreatment biopsies predicts response of rectal cancers to neoadjuvant radiochemotherapy. Int J Radiat Oncol Biol Phys. 2006;64:466-472. (Pubitemid 43083434)
10. Qiu H, Sirivongs P, Rothenberger M, et al. Molecular prognostic factors in rectal cancer treated by radiation and surgery. Dis Colon Rectum. 2000;43: 451-459. (Pubitemid 30225425)
11. Garcia-Aguilar J, Chen Z, Smith DD, et al. Identification of a biomarker profile associated with resistance to neoadjuvant chemoradiation therapy in rectal cancer. Ann Surg. 2011;254:486-492.
12. Lin JT, Chang TH, Chang CS, et al. Prognostic value of pretreatment CD44 mRNA in peripheral blood of patients with locally advanced head and neck cancer. Oral Oncol. 2010;46:e29-e33.
13. Relf M, LeJeune S, Scott PA, et al. Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Res. 1997;57:963-969. (Pubitemid 27098025)
14. Toi M, Atiqur Rahman M, Bando H, et al. Thymidine phosphorylase (plateletderived endothelial-cell growth factor) in cancer biology and treatment. Lancet Oncol. 2005;6:158-166. (Pubitemid 40309127)
15. Zlobec I, Steele R, Compton CC. VEGF as a predictive marker of rectal tumor response to preoperative radiotherapy. Cancer. 2005;104:2517-2521. (Pubitemid 41691576)
16. Chang HJ, Jung KH, Kim DY, et al. Bax, a predictive marker for therapeutic response to preoperative chemoradiotherapy in patients with rectal carcinoma. Hum Pathol. 2005;36:364-371. (Pubitemid 40591806)
17. Kandioler D, Zwrtek R, Ludwig C, et al. TP53 genotype but not p53 immunohistochemical result predicts response to preoperative short-term radiotherapy in rectal cancer. Ann Surg. 2002;235:493-498. (Pubitemid 34258347)
18. Rodel F, Hoffmann J, Distel L, et al. Survivin as a radioresistance factor, and prognostic and therapeutic target for radiotherapy in rectal cancer. Cancer Res. 2005;65:4881-4887. (Pubitemid 40740827)
19. Kojima M, Ishii G, Atsumi N, et al. CD133 expression in rectal cancer after preoperative chemoradiotherapy. Cancer Sci. 2010;101:906-912.
20. Speake WJ, Dean RA, Kumar A, et al. Radiation induced MMP expression from rectal cancer is short lived but contributes to in vitro invasion. Eur J Surg Oncol. 2005;31:869-874. (Pubitemid 41435256)
21. Diez M, Ramos P, Medrano MJ, et al. Preoperatively irradiated rectal carcinoma: analysis of the histopathologic response and predictive value of proliferating cell nuclear antigen immunostaining. Oncology. 2003;64:213-219. (Pubitemid 36438805)
22. Willett CG, Warland G, Hagan MP, et al. Tumor proliferation in rectal cancer following preoperative irradiation. J Clin Oncol. 1995;13:1417-1424.
23. Huh JW, Kim HR. Postoperative chemotherapy after neoadjuvant chemoradiation and surgery for rectal cancer: is it essential for patients with ypT0-2N0? J Surg Oncol. 2009;100:387-391.
24. Huh JW, Kim HR, Kim YJ. Proliferating cell nuclear antigen as a prognostic factor after total mesorectal excision of stage II-III rectal cancer. Ann Surg Oncol. 2009;16:1494-1500.
25. Rodel C, Martus P, Papadoupolos T, et al. Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer. J Clin Oncol. 2005;23:8688-8696. (Pubitemid 46211512)
26. Zhou BB, Zhang H, Damelin M, et al. Tumour-initiating cells: challenges and opportunities for anticancer drug discovery. Nat Rev Drug Discov. 2009;8: 806-823.
27. Lagadec C, Vlashi E, Della Donna L, et al. Survival and self-renewing capacity of breast cancer initiating cells during fractionated radiation treatment. Breast Cancer Res. 2010;12:R13.
28. Diehn M, Cho RW, Lobo NA, et al. Association of reactive oxygen species levels and radioresistance in cancer stem cells. Nature. 2009;458: 780-783.
29. Bao S,Wu Q,McLendon RE, et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature. 2006;444: 756-760. (Pubitemid 44949604)
30. Phillips TM, McBride WH, Pajonk F. The response of CD24(-/low)/CD44 +breast cancer-initiating cells to radiation. J Natl Cancer Inst. 2006;98: 1777-1785. (Pubitemid 46017929)
31. Zoller M. CD44: can a cancer-initiating cell profit from an abundantly expressed molecule? Nat Rev Cancer. 2011;11:254-267.
32. Maula SM, LuukkaaM, Grenman R, et al. Intratumoral lymphatics are essential for the metastatic spread and prognosis in squamous cell carcinomas of the head and neck region. Cancer Res. 2003;63:1920-1926. (Pubitemid 36460859)
33. Xiao W, Graham PH, Power CA, et al. CD44 is a biomarker associated with human prostate cancer radiation sensitivity. Clin ExpMetastasis. 2012;29:1-9.
34. Dubben HH, Thames HD, Beck-Bornholdt HP. Tumor volume: a basic and specific response predictor in radiotherapy. Radiother Oncol. 1998;47: 167-174. (Pubitemid 28275927)
35. Bentzen SM, Thames HD. Tumor volume and local control probability: clinical data and radiobiological interpretations. Int J Radiat Oncol Biol Phys. 1996;36:247-251. (Pubitemid 26314173)
36. Hu W, Kavanagh JJ. Anticancer therapy targeting the apoptotic pathway. Lancet Oncol. 2003;4:721-729. (Pubitemid 37527207)
37. Kim JS, Kim JS, Cho MJ, et al. Preoperative chemoradiation using oral capecitabine in locally advanced rectal cancer. Int J Radiat Oncol Biol Phys. 2002;54:403-408.
38. Sauer R, Becker H, Hohenberger W, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med. 2004;351:1731-1740.
39. MacCallum RC, Zhang S, Preacher KJ, et al. On the practice of dichotomization of quantitative variables. Psychol Methods. 2002;7:19-40.